NASDAQ:UPB Upstream Bio Q3 2024 Earnings Report $10.72 -0.32 (-2.90%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$10.72 0.00 (0.00%) As of 07/18/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Upstream Bio EPS ResultsActual EPS-$6.96Consensus EPS -$0.58Beat/MissMissed by -$6.38One Year Ago EPSN/AUpstream Bio Revenue ResultsActual Revenue$0.61 millionExpected Revenue$0.83 millionBeat/MissMissed by -$220.00 thousandYoY Revenue GrowthN/AUpstream Bio Announcement DetailsQuarterQ3 2024Date11/7/2024TimeN/AConference Call DateThursday, November 7, 2024Conference Call Time7:00AM ETUpcoming EarningsUpstream Bio's Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Upstream Bio Earnings HeadlinesUpstream Bio begins phase 2 COPD trial for verekitugJuly 10, 2025 | uk.investing.comUpstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory PortfolioJuly 8, 2025 | quiverquant.comQCongress Is Talking Crypto. Here’s What It Means for You …Congress is deep into “Crypto Week” — with new bills that could finally bring clarity to digital assets. Crypto analyst Juan Villaverde says Bitcoin will likely keep climbing… but smaller coins could deliver far bigger gains. He’s revealing the altcoins he believes are best positioned for this new regulatory era.July 20 at 2:00 AM | Weiss Ratings (Ad)Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)July 8, 2025 | globenewswire.comUPB Upstream Bio, Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comUpstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody SpaceJune 16, 2025 | tipranks.comSee More Upstream Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email. Email Address About Upstream BioUpstream Bio (NASDAQ:UPB) (NASDAQ: UPB) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision immune protease inhibitors for the treatment of inflammatory and fibrotic diseases. The company’s proprietary platform enables selective targeting of key proteases involved in immune cell regulation, with the goal of modulating disease pathways and reducing systemic side effects typically associated with broad-spectrum immunosuppression. Upstream Bio’s pipeline comprises multiple programs in clinical development, including candidates aimed at addressing chronic pulmonary and autoimmune conditions characterized by dysregulated neutrophil and macrophage activity. Research and development efforts leverage deep insights into protease biology to pursue indications with high unmet medical need and to optimize therapeutic profiles across patient populations. Since its inception, Upstream Bio has established collaborations with academic institutions and industry partners to advance its drug candidates. The company is headquartered in the United States and is exploring opportunities for global patient access through strategic licensing and partnership agreements.Written by Jeffrey Neal JohnsonView Upstream Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)America Movil (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
